Cathie Wood’s ARK Invest Buys Nearly 60,000 Shares of CRISPR

A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday. Specifically, these exchange-traded funds bought roughly $4.6 million worth of CRISPR Therapeutics AG (NASDAQ: CRSP), as the prices of these funds were down about 1% on Wednesday. Note that their performance is fairly negative in the past year.

ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 14,400 shares of CRISPR, and ARK Innovation ETF (NYSEARCA: ARKK) scooped up 45,500 shares. At Wednesday’s closing price, this would have valued the sales at roughly $4.6 million altogether. Even though this is a small fraction of their total holdings, every little bit counts. The innovation ETF is down about 24% and the other is down closer to 36% in the past year.

Check out all the ARK Invest trades for Wednesday as well:

Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of 247wallst.com.

ALSO READ: Why Old-School Dividend-Paying Tech Stocks Are Outstanding 2022 Ideas

Source: Read Full Article